United States: FDA Issues Draft Guidance Addressing Postmarket Submission Requirements For Internet-based Promotional Materials

On January 14, 2014, the U.S. Food and Drug Administration (Agency) published a long-awaited draft guidance entitled Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics.  The draft guidance, which describes how firms may fulfill the postmarket requirement to submit promotional statements when such statements are disseminated or published via internet-based media, represents the Agency's first step towards fulfilling the Food and Drug Administration Safety and Innovation Act's requirement that the Agency provide, by July 9, 2014, formal guidance on the manner in which it intends to regulate the publication and dissemination of promotional materials on the internet.


On January 14, 2014, the U.S. Food and Drug Administration (FDA or Agency) published a long-awaited draft guidance entitled Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics.  This On the Subject provides an overview of the draft guidance and its implications for regulated firms.

The FDA has long acknowledged industry's need for comprehensive guidance on internet and social media promotion of regulated products.  Indeed, in November 2009, the Agency held a public meeting and established an electronic docket that afforded interested entities the opportunity to provide comments on this topic, and in December 2011, it issued a related draft guidance that included recommendations for responding to electronically submitted, unsolicited requests for off-label information (summary here).

The Agency has not, however, issued detailed guidance on most topics related to internet promotion of FDA-regulated products.  For example, the Federal Food, Drug and Cosmetic Act (FDCA) requires the holder of a marketing approval for a prescription drug or biologic to submit all promotional labeling and advertisements to the FDA at the time of initial dissemination (for labeling) or at the time of initial publication (for advertisements).  Similarly, federal regulations require the holder of a marketing approval for an animal drug to submit one set of specimens of any mailing pieces and other labeling at the time of initial dissemination and one set of specimens for any advertisement at the time of initial publication or broadcast.  Increased development and use of social media, however, has increased the total number of communications that may be viewed as promotional and has enabled many such communications to be published in real time.  As such, it may be difficult—if not impossible—for firms to submit all promotional labeling and advertising pieces at the time of initial dissemination or publication.

In recognition of this issue, on January 14, 2014, the FDA issued the first in an expected series of long-awaited draft guidance documents regarding internet/social media promotion of FDA-regulated products.  It describes how firms may fulfill the postmarket requirement to submit promotional statements when such statements are disseminated or published via "interactive promotional media."  The draft guidance, which is entitled Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics, addresses three major issues:

  1. Definition of the term "interactive promotional media"
  2. Factors the Agency considers in determining whether a postmarketing submission is required for interactive promotional media
  3. Recommendations for submitting interactive promotional media materials to the Agency

What is interactive promotional media?

The draft guidance applies to promotional statements made via "interactive promotional media," which the FDA describes as including "modern tools and technologies that often allow for real-time communications and interactions (e.g., blogs, microblogs, social networking sites, online communities, and live podcasts) that firms use to promote their drugs."  For example, the draft guidance applies to promotional statements made via Twitter, Facebook, websites and message boards.

What factors will the FDA consider in determining whether a firm is required to submit promotional statement(s) made via interactive promotional media?

The Agency proposes to consider the following factors when determining whether it expects a firm to submit postmarket promotional statements:

  • A firm is responsible for product promotional communications on sites that are owned, controlled, created, influenced or operated by or on behalf of the firm.  The Agency will consider whether the firm, or anyone acting on behalf of the firm, influences or controls the promotional activity or communication in whole or in part.  A firm is responsible for submitting promotional materials if it exerts influence over a site "in any particular"—e.g., collaborates on or has editorial, preview or review privileges over the content provided—even if its influence is limited in scope.
  • Under certain circumstances, a firm is responsible for promotion on third-party sites.  A firm is responsible for submitting promotional materials on a third-party site if the firm has any control or influence over the third-party site, even if that influence is limited in scope.  If a firm provides only financial support (e.g., through an unrestricted educational grant) and has no other control or influence over the site, however, the firm has no obligation to submit the content to FDA.  Moreover, if a firm provides promotional material to be used on a third-party site but does not direct the placement of the promotional material or have any control or influence over the site, the firm needs only to submit the promotional content that it contributed, not the content of the site as a whole.
  • A firm is responsible for the content produced by an employee or agent who is acting on behalf of the firm to promote the firm's product.  A firm is responsible for submitting user-generated promotional content (e.g., comments on a message board) and communications of its employees or anyone acting on its behalf.  FDA recommends that a firm be transparent in disclosing its involvement on a site by clearly identifying the user-generated content and communications of its employees or entities acting on its behalf.  Importantly, a firm is generally not responsible, however, for content that is truly independent of the firm (i.e., not produced by or on behalf of the firm and not prompted by the firm in any particular).  As such, FDA will not ordinarily view user-generated content on firm-owned or -controlled venues, such as blogs, message boards and chat rooms, as promotional content on behalf of the firm, as long as the poster has no affiliation with the firm and the firm had no influence on the user-generated content. 

How does the Agency recommend that a firm submit promotional statements made in interactive promotional media?

The Agency intends to exercise enforcement discretion with respect to the postmarket submission requirement if the firm submits interactive promotional media, as described below:

  • At the time of initial display, a firm should submit in its entirety all sites for which it is responsible [on Form FDA 2253 (for human drugs and biologics) or 2301 (for animal drugs)].  The firm should submit the comprehensive static product website, with the addition of the interactive or real-time components, and include annotations to describe the parts that are interactive and allow for real-time communications.  Any subsequent changes should be annotated and resubmitted to the Agency at the time of initial display.  The firm should also provide a cross-reference by noting the submission date of the most recent version of the site.  After the initial submission or resubmission, however, if the site is publically accessible without restrictions, such as password or subscription (nonrestricted), and remains unchanged other than displaying real-time information, the FDA does not intend to object if the firm submits an updated listing of the site that does not include screenshots or other visual representations of the actual interactive or real-time communication.
  • For third-party sites on which a firm's participation is limited to active or real-time communications, a firm should submit the homepage of the third-party site, along with the interactive page within the third-party site and the firm's first communication at the time of initial display.  The firm may include any annotations that describe its communications within the third-party site.  After the initial submission, if the firm remains an active participant on the third-party site and that site is nonrestricted, FDA does not intend to object if the firm submits an updated listing of the website that does not include screenshots or other visual representations of the actual interactive or real-time communication.
  • Once every month, a firm should submit an updated listing of all nonrestricted sites for which it is responsible or in which it remains an active participant and that include interactive or real-time communications.  Firms need not submit screenshots or other visual representations of the actual interactive or real-time communications with the monthly updates.  Multiple sites and the corresponding documents can be submitted with a single form.  Firms should include a separate document for each site, however, that includes the site name, URL and date range, as well as a cross-reference to the date of the most recent submission of the site.
  • If a site has restricted access and, as such, FDA may not have access to the site, a firm should submit all content related to the discussion (e.g., all user-generated content about the topic), which may or may not include independent user-generated content, to adequately provide context to facilitate the review.  Screenshots or other visual representations of the actual site, including the interactive or real-time communications, should be submitted monthly.
  • When submitting the site, FDA recommends that a firm take formatting factors (e.g., appearance, layout, visual impression) into consideration to enable the Agency to view the communications as a whole. 

Stakeholders interested in commenting on the draft guidance should submit comments to the FDA by April 14, 2014.

Implications

The Food and Drug Administration Safety and Innovation Act (FDASIA) requires the FDA to issue comprehensive guidance describing its policy on the promotion of regulated medical products on the internet (including social media) by July 9, 2014.  This draft guidance represents the Agency's first step towards meeting this broader requirement. 

In general, the draft guidance takes a position consistent with the extent to which the Agency currently regulates promotional material—firms are responsible for the content and submission of promotional items that they own, control, create, influence or operate (either by themselves or through an agent), as well as items created by employees or agents.  The Agency's clear statement that firms are not responsible for user-generated content that is truly independent is significant and should be welcomed by companies desiring to expand their presence in social media.

The submission(s) required to fall within enforcement discretion appear to strike a reasonable balance between the Agency's mandate to review promotional materials and the excessive burden on the Agency and on industry if the Agency reviewed all promotional materials disseminated through interactive promotional media.  Although the initial submission requirements do not distinguish between open-access and restricted websites, the Agency has proposed to impose less burdensome subsequent submission requirements for open-access websites, i.e., websites that the Agency can access on its own.  Accordingly, to reduce the burden associated with meeting the submission requirement, firms may choose to limit promotional statements made in a password-protected (non-open-access) environment.

Notwithstanding the above, the draft guidance leaves a number of critical issues unaddressed.  For example:

  • Content.  What type of content is appropriate for publication or dissemination via interactive promotional media?  Under what circumstances should a firm provide a copy of product labeling with posted information?  Is a link to product labeling sufficient, or should a copy of the labeling be attached or relevant information from labeling be spelled out in the post itself?  When (and what type) of critical information (e.g., full indication statements (with important limitations), black box warnings, contraindications and adverse events) should be included? 
  • Responding to Inquiries Regarding off-label Use.  How should a firm respond to externally originated inquiries regarding off-label use?  If the question is posed to the general public, may the firm respond to the general public, or should the firm respond via private message to the specific external user that posed the question?  Is there an obligation to remove such questions from the website?  If so, within what time frame?
  • Factors for Determining When an Employee or Agent Is Acting on Behalf of the Company.  How will the Agency make this determination—should it consider the manner in which the employee or agency represents himself (or herself) to readers of the post?  The content of the message?  Policies and procedures established by manufacturers?  The date and/or time at which the information was posted?  How will the FDA treat comments of a third party (e.g., a blogger) that goes beyond the scope of the agency agreement?  
  • Microblogs.  Given space limitations, should microblogs be treated differently than other internet-based promotional media?     

Interested parties should monitor communications from the FDA during the next few months to stay apprised of the Agency's progress in providing its broader guidance on social media and internet promotion.  As guidance documents are posted by the Agency, firms may wish to consider updating applicable policies and procedures to facilitate compliance.  In the meantime, it remains to be seen whether, based on this draft guidance, regulated firms will increase their use of interactive media given the general reluctance (until now), in view of the FDA's enforcement activities in recent years relating to internet- based communications, including, for example, the use of Facebook.    

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions